SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic

N Engl J Med. 2021 Sep 9;385(11):961-964. doi: 10.1056/NEJMp2106970. Epub 2021 Jul 21.

Authors

Garth Rapeport¹, Emma Smith¹, Anthony Gilbert¹, Andrew Catchpole¹, Helen McShane¹, Christopher Chiu¹

Affiliation

¹ From the National Heart and Lung Institute (G.R., E.S.) and the Department of Infectious Disease (C.C.), Imperial College London; the U.K. Vaccines Taskforce (A.G.); and hVIVO Services (A.C.) - all in London; and the Department of Paediatrics, University of Oxford, Oxford, United Kingdom (H.M.).

PMID: 34289273
DOI: 10.1056/NEJMp2106970

No abstract available

MeSH terms

Antiviral Agents / therapeutic use*
COVID-19 Vaccines*
COVID-19* / immunology
COVID-19* / prevention & control
COVID-19* / therapy
Clinical Trials as Topic / ethics
Clinical Trials as Topic / organization & administration*
Human Experimentation / standards*
Humans
SARS-CoV-2*

Substances

Antiviral Agents
COVID-19 Vaccines

Grants and funding

MR/R005982/1/MRC_/Medical Research Council/United Kingdom